Browse TFAP2A

Summary
SymbolTFAP2A
Nametranscription factor AP-2 alpha (activating enhancer binding protein 2 alpha)
Aliases AP-2; TFAP2; AP2TF; transcription factor AP-2 alpha (activating enhancer-binding protein 2 alpha); AP-2alpha ......
Chromosomal Location6p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF03299 Transcription factor AP-2
Function

Sequence-specific DNA-binding protein that interacts with inducible viral and cellular enhancer elements to regulate transcription of selected genes. AP-2 factors bind to the consensus sequence 5'-GCCNNNGGC-3' and activate genes involved in a large spectrum of important biological functions including proper eye, face, body wall, limb and neural tube development. They also suppress a number of genes including MCAM/MUC18, C/EBP alpha and MYC. AP-2-alpha is the only AP-2 protein required for early morphogenesis of the lens vesicle. Together with the CITED2 coactivator, stimulates the PITX2 P1 promoter transcription activation. Associates with chromatin to the PITX2 P1 promoter region.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001503 ossification
GO:0001654 eye development
GO:0001655 urogenital system development
GO:0001822 kidney development
GO:0002072 optic cup morphogenesis involved in camera-type eye development
GO:0003404 optic vesicle morphogenesis
GO:0003407 neural retina development
GO:0003409 optic cup structural organization
GO:0007423 sensory organ development
GO:0007605 sensory perception of sound
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010039 response to iron ion
GO:0010842 retina layer formation
GO:0010944 negative regulation of transcription by competitive promoter binding
GO:0016331 morphogenesis of embryonic epithelium
GO:0021545 cranial nerve development
GO:0021557 oculomotor nerve development
GO:0021559 trigeminal nerve development
GO:0021602 cranial nerve morphogenesis
GO:0021603 cranial nerve formation
GO:0021622 oculomotor nerve morphogenesis
GO:0021623 oculomotor nerve formation
GO:0021675 nerve development
GO:0021783 preganglionic parasympathetic fiber development
GO:0030278 regulation of ossification
GO:0030282 bone mineralization
GO:0030326 embryonic limb morphogenesis
GO:0030500 regulation of bone mineralization
GO:0030501 positive regulation of bone mineralization
GO:0031076 embryonic camera-type eye development
GO:0031214 biomineral tissue development
GO:0034505 tooth mineralization
GO:0035107 appendage morphogenesis
GO:0035108 limb morphogenesis
GO:0035113 embryonic appendage morphogenesis
GO:0035115 embryonic forelimb morphogenesis
GO:0035136 forelimb morphogenesis
GO:0042471 ear morphogenesis
GO:0042472 inner ear morphogenesis
GO:0042476 odontogenesis
GO:0042481 regulation of odontogenesis
GO:0042482 positive regulation of odontogenesis
GO:0043010 camera-type eye development
GO:0043523 regulation of neuron apoptotic process
GO:0043525 positive regulation of neuron apoptotic process
GO:0043583 ear development
GO:0045778 positive regulation of ossification
GO:0048048 embryonic eye morphogenesis
GO:0048483 autonomic nervous system development
GO:0048486 parasympathetic nervous system development
GO:0048532 anatomical structure arrangement
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048592 eye morphogenesis
GO:0048593 camera-type eye morphogenesis
GO:0048596 embryonic camera-type eye morphogenesis
GO:0048701 embryonic cranial skeleton morphogenesis
GO:0048704 embryonic skeletal system morphogenesis
GO:0048705 skeletal system morphogenesis
GO:0048706 embryonic skeletal system development
GO:0048736 appendage development
GO:0048839 inner ear development
GO:0050954 sensory perception of mechanical stimulus
GO:0051402 neuron apoptotic process
GO:0060021 palate development
GO:0060041 retina development in camera-type eye
GO:0060042 retina morphogenesis in camera-type eye
GO:0060173 limb development
GO:0060348 bone development
GO:0060349 bone morphogenesis
GO:0060900 embryonic camera-type eye formation
GO:0061029 eyelid development in camera-type eye
GO:0070167 regulation of biomineral tissue development
GO:0070169 positive regulation of biomineral tissue development
GO:0070170 regulation of tooth mineralization
GO:0070172 positive regulation of tooth mineralization
GO:0070997 neuron death
GO:0071241 cellular response to inorganic substance
GO:0071248 cellular response to metal ion
GO:0071281 cellular response to iron ion
GO:0072001 renal system development
GO:0072593 reactive oxygen species metabolic process
GO:0090596 sensory organ morphogenesis
GO:1901214 regulation of neuron death
GO:1901216 positive regulation of neuron death
GO:1904888 cranial skeletal system development
GO:1990267 response to transition metal nanoparticle
GO:2000027 regulation of organ morphogenesis
GO:2000377 regulation of reactive oxygen species metabolic process
GO:2000378 negative regulation of reactive oxygen species metabolic process
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001078 transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003682 chromatin binding
GO:0003713 transcription coactivator activity
Cellular Component GO:0005813 centrosome
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-8866907: Activation of the TFAP2 (AP-2) family of transcription factors
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-392499: Metabolism of proteins
R-HSA-8866904: Negative regulation of activity of TFAP2 (AP-2) family transcription factors
R-HSA-597592: Post-translational protein modification
R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins
R-HSA-2990846: SUMOylation
R-HSA-3232118: SUMOylation of transcription factors
R-HSA-8866911: TFAP2 (AP-2) family regulates transcription of cell cycle factors
R-HSA-8866910: TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
R-HSA-8866906: TFAP2 (AP-2) family regulates transcription of other transcription factors
R-HSA-8869496: TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation
R-HSA-8864260: Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors
Summary
SymbolTFAP2A
Nametranscription factor AP-2 alpha (activating enhancer binding protein 2 alpha)
Aliases AP-2; TFAP2; AP2TF; transcription factor AP-2 alpha (activating enhancer-binding protein 2 alpha); AP-2alpha ......
Chromosomal Location6p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TFAP2A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolTFAP2A
Nametranscription factor AP-2 alpha (activating enhancer binding protein 2 alpha)
Aliases AP-2; TFAP2; AP2TF; transcription factor AP-2 alpha (activating enhancer-binding protein 2 alpha); AP-2alpha ......
Chromosomal Location6p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TFAP2A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTFAP2A
Nametranscription factor AP-2 alpha (activating enhancer binding protein 2 alpha)
Aliases AP-2; TFAP2; AP2TF; transcription factor AP-2 alpha (activating enhancer-binding protein 2 alpha); AP-2alpha ......
Chromosomal Location6p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TFAP2A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.1120.155
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.9030.724
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.2520.556
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3830.502
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.1720.575
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6120.817
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0430.953
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2740.893
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1470.946
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-2.0560.0299
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.8440.131
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0750.75
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TFAP2A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTFAP2A
Nametranscription factor AP-2 alpha (activating enhancer binding protein 2 alpha)
Aliases AP-2; TFAP2; AP2TF; transcription factor AP-2 alpha (activating enhancer-binding protein 2 alpha); AP-2alpha ......
Chromosomal Location6p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TFAP2A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTFAP2A
Nametranscription factor AP-2 alpha (activating enhancer binding protein 2 alpha)
Aliases AP-2; TFAP2; AP2TF; transcription factor AP-2 alpha (activating enhancer-binding protein 2 alpha); AP-2alpha ......
Chromosomal Location6p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TFAP2A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TFAP2A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTFAP2A
Nametranscription factor AP-2 alpha (activating enhancer binding protein 2 alpha)
Aliases AP-2; TFAP2; AP2TF; transcription factor AP-2 alpha (activating enhancer-binding protein 2 alpha); AP-2alpha ......
Chromosomal Location6p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TFAP2A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTFAP2A
Nametranscription factor AP-2 alpha (activating enhancer binding protein 2 alpha)
Aliases AP-2; TFAP2; AP2TF; transcription factor AP-2 alpha (activating enhancer-binding protein 2 alpha); AP-2alpha ......
Chromosomal Location6p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TFAP2A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTFAP2A
Nametranscription factor AP-2 alpha (activating enhancer binding protein 2 alpha)
Aliases AP-2; TFAP2; AP2TF; transcription factor AP-2 alpha (activating enhancer-binding protein 2 alpha); AP-2alpha ......
Chromosomal Location6p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TFAP2A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTFAP2A
Nametranscription factor AP-2 alpha (activating enhancer binding protein 2 alpha)
Aliases AP-2; TFAP2; AP2TF; transcription factor AP-2 alpha (activating enhancer-binding protein 2 alpha); AP-2alpha ......
Chromosomal Location6p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TFAP2A collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.